Learn More
PURPOSE The aim of this multicenter-study was to evaluate the progression-free survival, response rate and toxicity of the combination of bendamustine and rituximab (BR) in patients with mantle cell(More)
6637 Background: Allogeneic hematopoietic cell transplantation from matched unrelated donors (MUD-HSCT) may be curative for high risk AML patients. However, it carries a considerable risk of(More)
  • 1